Dr. William R. Strohl received his Ph.D. in Microbiology from Louisiana State University, and worked as a guest researcher at the GBF in Braunschweig, Germany. From 1980 to 1997, he rose from Assistant to Full Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University, Columbus, OH. There he pursued the molecular biology and biochemistry of polyketide biosynthesis pathways, particularly doxorubicin, in actinomycetes, and the physiology of E. coli in computer-controlled high cell density fermentations. As part of the latter endeavor, Dr. Strohl designed, implemented, and equipped a P2 fermentation facility at The Ohio State University (in 1994). Dr. Strohl moved to Merck in 1997 to head up Natural Products Microbiology, which he did for 4 years before being asked to start a new department in the field of recombinant monoclonal antibodies. From 2001 to 2008, Dr. Strohl was a leader in Merck's efforts to develop therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. As part of this effort, Dr. Strohl was the scientific leader in the acquisition and integration of Abmaxis and GlycoFi into the Merck Biologics organization. In April, 2008, Dr. Strohl was named leader of Antibody Drug Discovery at Centocor (J&J). Concomitant with the evolution of Biologics at Johnson & Johnson to serve additional therapeutic areas beyond Immunology and Oncology, in 2009 Dr. Strohl was named as VP and Head, Biologics Research, the biologics discovery department within the Biotechnology Center of Excellence. In 2013, Dr. Strohl was named as VP and Head, Biotechnology COE, Janssen R&D. Dr. Strohl has over 120 publications and 11 issued patents, has edited two books, and has recently written a book entitled "Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry", which was published in October, 2012.